Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Keith W. Pratz, MD

Keith W. Pratz, MD Physician

Director, Leukemia Program Clinical Associate of Medicine

Dr. Pratz is employed by Penn Medicine.

Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Hematology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2005
  • Medical Oncology, 2009

Clinical Expertise:

  • Acute Promyelocytic Leukemia
  • Adult T-Cell Leukemia
  • Adult T-Cell Lymphoma
  • AIDS Related Malignancies
  • Amyloidosis
  • Anaplastic Large Cell Lymphoma
  • Blood Cancer
  • Bone Marrow Biopsy
  • Bone Marrow Failure Syndromes
  • Burkitt Lymphoma
  • Cancer During Pregnancy
  • Castleman Disease
  • Chronic Lymphocytic Leukemia
  • Chronic Myelocytic Leukemia
  • CNS Lymphoma
  • Cutaneous Lymphoma
  • Eosinophilic Granuloma
  • Erdheim-Chester Disease
  • Essential Thrombocytosis
  • Graft Versus Host Disease
  • Hairy Cell Leukemia
  • Hematologic Malignancies
  • Histiocytosis
  • HIV Lymphoma
  • HIV Malignancies
  • Hodgkin Lymphoma
  • Intraocular Lymphoma
  • Large Granular Lymphocytic Leukemia
  • Light Chain Disorders
  • Lymphoma
  • Marginal Zone Lymphoma
  • Mediastinal Lymphoma
  • Monoclonal Gammopathy of Undetermined Significance
  • Mucosa-Associated Lymphoid Tissue Lymphoma
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Pelvic Malignancy During Pregnancy
  • Peripheral T-Cell Lymphoma
  • Plasma Cell Dyscrasia
  • POEMS Syndrome
  • Primary Myelofibrosis
  • Prolymphocytic Leukemia
  • Refractory Anemia With Excess Blasts
  • Sezary Syndrome
  • Transformed Lymphoma
  • Waldenstrom Macroglobulinemia (WM)
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Medicine and Dentistry of New Jersey
Residency: Mayo Clinic
Fellowship: Johns Hopkins Hospital

Memberships

Austrian Academy of Sciences, International Eastern Cooperative Oncology Group, Local National Cancer Institute, National National Comprehensive Cancer Network, National

Hospital Affiliation

Dr. Pratz is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, DeZern AE.: Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction. Leuk Res. 83 : 106174,2019.

Miller KP, Venkataraman G, Gocke CD, Batista DA, Borowitz MJ, Burns KH, Pratz K, Duffield AS.: Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. Am J Clin Pathol. : pii: aqz087.,2019.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.: Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 17 (6): 721-749,2019.

Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA, Webster J, Hess AD, Pratz KW, Karnitz LM, Kaufmann SH.: Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Sci Rep. 9 (1): 3617,2019.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.: A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol 94 (1): 111-117,2019.

Poh W, Dilley RL, Moliterno AR, Maciejewski JP, Pratz KW, McDevitt MA, Herman JG.: BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. Clin Cancer Res 28 : 2019.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A.: Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133 (1): 7-17,2019.

Liu T, Ivaturi V, Sabato P, Gobburu JVS, Greer JM, Wright JJ, Smith BD, Pratz KW, Rudek MA; ETCTN-6745 study team1.: Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11 (4): 435-443,2018.

Webster JA, Pratz KW.: Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma 59 (2): 274-287,2018.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.: Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19 (2): 216-228,2018.

Academic Contact Info

3400 Civic Center Blvd.
South Pavilion Room 12-155

Philadelphia, PA 19104
Patient appointments: 800-789-7366 (PENN)